PFIZER.NSE

Pfizer Ltd.

Pfizer shares rose after the U.S. drugmaker struck a deal with the Trump administration to sell key medicines at steep discounts through a new federal website.

Pharma, autos, and media stocks led early gains, while Tata Motors and Atlantaa were among top movers.

After eight days of losses, markets may see a cautious start as the RBI policy decision takes center stage. Stock-specific action is expected in pharma, auto, and PSU banking counters.

New Delhi, Sep 4 : The Department for Promotion of Industry and Internal Trade (DPIIT) has signed a Memorandum of Understanding (MoU) with US-based pharma giant Pfizer to strengthen Indias healthcare and accelerate the lab-to-market journey of healthcare innovations, the Ministry of Commerce and Industry said on Thursday. The collaboration will extend both financial and non-financial support to startups. Under the partnership, the Pfizer INDovation programme will empower DPIIT-recognised startups with grants of up to Rs 60 lakhs each, along with a tailored 18-month incubation programme delivered by Social Alpha. The programme will provide dedicated acceleration tracks covering clinical validation, regulatory approvals, and go-to-market strategies. Startups will also gain access to expert mentorship, infrastructure, and global networks, in addition to exposure at Pfizers Research and Development facilities in Chennai, enabling them to strengthen innovations with advanced industry insights, the Ministry said.

IOC, Vodafone Idea, Glenmark Pharma, and AstraZeneca Pharma, among others, are expected to post their quarterly earnings today. JSW Cement to list at 10 am.

Key inflation data and earnings from major companies such as HAL, ONGC, and Suzlon are expected to set the near-term tone.

ONGC, NHPC, NMDC, Zydus, and Bharat Dynamics, among others, are expected to post their quarterly earnings today. Highway Infrastructure is set to list on the mainboard today.

Pfizer Ltd's board has approved a five-year marketing and supply agreement with Mylan Pharmaceuticals for the brands Ativan and Pacitane, targeting the treatment of anxiety disorders and Parkinsonism. The partnership leverages Mylan's expertise in the central nervous system therapy area to enhance product distribution and engagement with neurologists and psychiatrists in India.